Steven Allen, MD

Associate Chief, Hematology, The Feinstein Institute for Medical Research

Professor of Medicine, Hofstra Northwell School Of Medicine

Phone: (516) 734-8959
Email: allen@northwell.edu

About the Investigator
Dr. Allen is Associate Chief of Hematology, Division of Medical Oncology and Hematology at North Shore University Hospital/LIJ Medical Center. His clinical practice is dedicated to the treatment of hematologic malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, benign hematologic disorders and coagulation.

Dr. Allen is board certified in internal medicine and hematology/medical oncology. He received his medical degree from the Johns Hopkins School of Medicine, completed his residency in Internal Medicine and served as a Hematology/Medical Oncology Fellow at New York Hospital.

Dr. Allen is Chair of the American Society of Hematology’s Committee on Practice, a member of the Society’s Executive Committee, and serves on its Task Force on Quality Measures, for which he received its Outstanding Service Award. Dr. Allen is Co-Chair of the AMA’s Physician Consortium for Performance Improvement – Hematology Work Group and an active member of numerous other medical boards and associations. He has authored or co-authored more than 100 original research papers and reviews and is Professor of Medicine at the Hofstra Northwell School of Medicine.

Research Focus
The goal of Dr. Allen’s proposed research is to investigate the signaling pathways in myeloproliferative diseases over the course of the disease. Understanding these mechanisms may allow for the development of more efficacious and better targeted therapies. This approach requires samples from individual patients with myeloproliferative diseases.

Through more than 25 years experience focusing on the treatment of hematologic malignancies, Dr. Allen has the expertise, leadership and motivation necessary to successfully carry out the proposed work. He has served as Principal Investigator or Co-Investigator for many clinical trials involving the treatment of patients with myelodysplastic syndrome and leukemia including studies involving close collaboration between the clinician and basic science laboratory. This has been done with great success in chronic lymphocytic leukemia where serial samples over time have been obtained and studied in collaboration with basic science laboratories.

Dr. Allen has been an active member of the National Cancer Institute sponsored Community Clinical Oncology Program participating in multiple Cooperative group clinical trials for patients with hematologic malignancies. He has successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers and produced over 100 peer-reviewed publications based upon these projects.

As a result of his previous experience, Dr. Allen is aware of the requirements to successfully undertake a clinical trial following good clinical practice guidelines. He has a demonstrated record of successful and productive myeloproliferative disease research in this patient population.

Education
The City College, New York NY
Degree: B.S.
1973
Field of Study: Chemistry

Johns Hopkins School of Medicine, Baltimore MD
Degree: M.D.
1977
Field of Study: Medicine

The New York Hospital, New York, NY
Degree: Intern/Resident
1980
Field of Study: Intern

The New York Hospital, New York, NY
Degree: Fellow
1983
Field of Study: Fellow, Hematology/Medical Oncology

Appointments
Academic Appointments
1982-1984 Instructor in Medicine, Cornell University Medical College
1984-1990 Assistant Professor of Medicine, Cornell University Medical College
1990-1996 Associate Professor of Clinical Medicine, Cornell University Medical College
1994-1996 Adjunct Associate Professor of Medicine, New York University School of Medicine
1994-2011
Adjunct Clinical Assoc. Professor of Medicine, New York College of Osteopathic Medicine
1996-1997 Adjunct Associate Professor of Clinical Medicine, Cornell University Medical College
1996-2007
Associate Professor of Medicine, New York University School of Medicine
2007-Present Professor of Clinical Medicine, Albert Einstein College of Medicine
2009-Present Professor of Medicine-Hofstra Northwell School of Medicine
2011-Present Adjunct Clinical Professor of Medicine, New York College of Osteopathic Medicine

Hospital Appointments
1977-1978 Intern in Medicine, The New York Hospital, New York, NY
1978-1979 Junior Assistant Resident, Internal Medicine, The New York Hospital, New York, NY
1979-1980 Senior Assistant Resident, Internal Medicine, The New York Hospital, New York, NY
1980-1983 Fellow, Hematology/Medical Oncology, The New York Hospital, New York, NY
1983-1985 Provisional Staff, North Shore University Hospital, Manhasset, NY
1985-1987 Assistant Attending Physician, North Shore University Hospital, Manhasset, NY
1987-1990 Senior Assistant Attending Physician, North Shore University Hospital, Manhasset, NY
1990-1995 Associate Attending, North Shore University Hospital, Manhasset, NY
1995-Present Attending Physician, North Shore University Hospital, Manhasset, NY
2000-Present Associate Investigator, Northwell Health Research Institute, Manhasset, NY
2000-Present Associate Chief, Division of Hematology, North Shore University Hospital, Manhasset, NY
2005-2006 Provisional Assistant Attending Physician, Long Island Jewish Medical Center
2006-2008 Assistant Attending Physician, Long Island Jewish Medical Center
2008-Present Attending Physician, Long Island Jewish Medical Center

Publications
  1. Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR. “Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.” Leukemia Research 34: 487-91, 2010.
  2. Cheng KL, Brody J, Warshall CE, Sloand EM, Allen SL. “Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinux.” Leukemia Research 34: e85-e87, 2010.
  3. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chiorazzi N. “Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed non-muscle myosin heavy chain IIA; implications for patient outcome and cell of origin.” Blood 115:3907-15, 2010.
  4. Donahue L, Shapira I, Shander A, Kolitz J, Allen S, Greenburg G. “Management of acute anemia in a Jehovah’s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature.” Transfusion 50:1561-7, 2010.
  5. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA. “P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.” Blood 116: 1413-21, 2010.
  6. Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swensen C, Louie AC. “First – in – man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.” Journal of Clinical Oncology 29: 979-85, 2011.
  7. Negrea OG, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. “Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin lymphoma.” Haematologica 96: 567-73, 2011.
  8. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W,Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA. “High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.” Leukemia Research 35: 329-33, 2011.
  9. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, Baskar S, Rader C, Mellstedt H, Rabbani H, Lee A, Gregersen PK, Rai KR, Chiorazzi N. “A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.” Blood 117: 5463-72, 2011.
  10. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES,Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. “Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.” Blood 117:5827-34,2011.

View more at PubMed